Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.
cefepime
neurotoxicity
therapeutic drug monitoring
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
10
2022
received:
20
08
2022
accepted:
29
10
2022
pubmed:
20
11
2022
medline:
8
2
2023
entrez:
19
11
2022
Statut:
ppublish
Résumé
Data evaluating cefepime thresholds associated with neurotoxicity remain limited. The objectives of this study were to evaluate the incidence of cefepime-related neurotoxicity (CRN) in patients with plasma cefepime concentrations, assess the relationship between cefepime exposure and CRN, investigate clinical factors associated with CRN, and describe electroencephalogram (EEG) abnormalities in CRN. This was a retrospective study of adult inpatients admitted between 2016 and 2018 who received cefepime therapeutic drug monitoring (TDM). Potential CRN cases were identified utilizing a standard definition. The primary outcomes of the study were to determine the incidence of CRN and evaluate the relationship between cefepime trough concentrations, the average daily AUC, and neurotoxicity. Bayesian posteriors were generated for each patient using a cefepime pharmacokinetic (PK) model, and the mean daily area under the concentration-time curve (AUC) was calculated. Multiple regression was performed to assess the association between CRN, cefepime PK, and clinical predictors of neurotoxicity. Four hundred eighty-one patients with 503 hospital encounters received cefepime TDM and were included in the analysis. The incidence of CRN was 4.4% (22/503). Patients with CRN had a higher incidence of renal dysfunction, hypertension, and diabetes mellitus compared to patients without CRN (non-NT). The mean cefepime trough concentration was significantly greater in the CRN patients than in the non-NT group (61.8 ± 33.7 vs. 30 ± 27.7 mg/L, respectively, p = 0.0002). Cefepime trough concentration and renal dysfunction were independently associated with increased risk of CRN in the adjusted multiple regression model. Moderate generalized slowing of the background rhythm was the most common EEG pattern associated with CRN. Delaying cefepime TDM greater than 72 h after the initiation of cefepime was associated with a 3-fold increased risk of CRN. Cefepime should be used cautiously in hospitalized patients with renal dysfunction due to the risk of neurotoxicity. Dose optimization utilizing TDM early in cefepime treatment may minimize adverse effects and improve patient safety.
Substances chimiques
Cefepime
807PW4VQE3
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6-14Informations de copyright
© 2022 Pharmacotherapy Publications, Inc.
Références
Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21(1):276.
Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe underappreciated encephalopathy. Crit Care. 2013;17(6):R264.
Boschung-Pasquier L, Atkinson A, Kastner LK, et al. Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort studies. Clin Microbiol Infect. 2020;26:333-339.
US Food and Drug Administration (FDA). FDA Drug Safety Communication: Cefepime and Risk of Seizure in Patients Not Receiving Dosage Adjustments for Kidney Impairment. US Food and Drug Administration; 2012.
Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS. Characterizing cefepime neurotoxicity: a systematic review. Open Forum Infect Dis. 2017;4(4):ofx170.
Bhattacharyya S, Darby RR, Raibagkar P, Gonzalez Castro LN, Berkowitz AL. Antibiotic-associated encephalopathy. Neurology. 2016;86:963-971.
Lee S-J. Cefepime-induced neurotoxicity. J Neurocrit Care. 2019;12(2):74-84.
Cusumano JA, Klinker K, Huttner A, et al. Towards precision medicine: therapeutic drug-monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity. Am J Health Syst Pharm. 2020;77(14):1104-1112.
Hagel S, Bach F, Brenner T, et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med. 2022;48(3):311-321.
Al-Shaer MH, Rubido E, Cherabuddi K, et al. Early therapeutic monitoring of beta-lactams and associated therapy outcomes in critically ill patients. J Antimicrob Chemother. 2020;75(12):3644-3651.
Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients. Clin Infect Dis. 2014;58(8):1072-1083.
Venugopalan V, Hamza M, Santevecchi B, et al. Implementation of a β-lactam therapeutic drug monitoring program: experience from a large academic medical center. Am J Health Syst Pharm. 2022;79(18):1586-1591.
Al-Shaer MH, Neely MN, Liu J, et al. Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing. Antimicrob Agents Chemother. 2020;64(9):e00745-20.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. 2017. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.
Hirsch LJ, LaRoche SM, Gaspard N, et al. American clinical neurophysiology Society's standardized critical care EEG terminology: 2012 version. J Clin Neurophysiol. 2013;30:1-27.
Beniczky S, Hirsch LJ, Kaplan PW, et al. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia. 2013;54:28-29.
Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy. 2006;26:1169-1174.
Lau C, Marriott D, Gould M, Andresen D, Reuter SE, Penm J. A retrospective study to determine the cefepime-induced neurotoxicity threshold in hospitalized patients. J Antimicrob Chemother. 2020;75:718-725.
Khan A, DeMott JM, Varughese C, et al. Effect of Cefepime on neurotoxicity development in critically ill adults with renal dysfunction. Chest. 2020;158(1):157-163.
Huwyler T, Lenggenhager L, Abbas M, et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect. 2017;23:454-459.
Vercheval C, Sadzot B, Maes N, Denooz R, Damas P, Frippiat F. Continuous infusion of cefepime and neurotoxicity: a retrospective cohort study. Clin Microbiol Infect. 2020;27(5):731-735. doi:10.1016/j.cmi.2020.07.003
Haddad NA, Schreier DJ, Fugate JE, et al. Incidence and predictive factors associated with Beta-lactam neurotoxicity in the critically ill: a retrospective cohort study. Neurocrit Care. 2022;37(1):73-80.
Rhodes NJ, Kuti JL, Nicolau DP, Neely MN, Nicasio AM, Scheetz MH. An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. J Infect Chemother. 2016;22(2):78-83.
Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010;54(10):4360-4367.
Pickkers P, Darmon M, Hoste E, et al. Acute kidney injury in the critically ill: an updated review on pathophysiology and management. Intensive Care Med. 2021;47(8):835-850.
Maan G, Keitoku K, Kimura N, et al. Cefepime-induced neurotoxicity: systematic review. J Antimicrob Chemother. 2022;77:2908-2921. doi:10.1093/jac/dkac271
Arend E, Christensen M. Delirium in the intensive care unit: a review. Nurs Crit Care. 2009;14(3):145-154.
Cefepime [Package Insert]. Baxter International Inc; 2016.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10.
Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother. 2002;50(3):425-428.
Sumi CD, Heffernan AJ, Lipman A, Roberts JA, Sime FB. What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review. Clin Pharmacokinet. 2019;58(11):1407-1443.
Delanaye P, Cavalier E, Pottel H. Serum creatinine: not so simple! Nephron. 2017;136(4):302-308.
Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant. 2008;23(3):966-970.
Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systemic review. J Am Soc Nephrol. 2006;17(7):2034-2047.
Li HT, Lee CH, Wu T, et al. Clinical, electroencephalographic features and prognostic factors of cefepime-induced neurotoxicity: a retrospective study. Neurocrit Care. 2019;31(2):329-337.
Wong G, Briscoe S, Adnan S, et al. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57:6165-6170.
Al-Shaer MH, Alghamdi WA, Graham E, Peloquin CA. Meropenem, cefepime, and piperacillin protein binding in patient samples. Ther Drug Monit. 2020;42(1):129-132.